Gastroenteropancreatic endocrine tumours; (GEP ETs) represent a relatively rare and heterogeneous group of neoplasms whose therapy can be challenging. The poorly differentiated, fast-growing cases are treated with chemotherapy. In the slow-growing ones, biotherapy is usually performed. Several categories of targeted therapies have been studied for their treatment in vitro and in vivo. A critical review of molecular alterations suggests a rationale for targeting angiogenesis, and the phosphatidylinositol 3 kinase (PI(3)K)/AKT/mammalian target of rapamycin (mTOR) pathway. Accordingly, antiangiogenic agents and mTOR inhibitors are presently the most tested agents in phase II and III studies. Bevacizumab, some multitarget inhibitors, and mTOR inhibitors showed promising results in patients with advanced GEP ETs. A limited activity has been reported for imatinib and epidermal growth factor receptor (EGFR) inhibitors. Combinations of molecular targeted therapies with different sites of action, and somatostatin analogues may be relevant to avoid molecular escape pathways. Future trials should include more homogeneous groups of patients and pay more attention to the subgroup with progressive disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives / Gabriele, Capurso; Nicola, Fazio; Stefano, Festa; Panzuto, Francesco; Filippo De Braud, ; DELLE FAVE, Gianfranco. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 72:2(2009), pp. 110-124. [10.1016/j.critrevonc.2009.01.008]

Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives

Francesco Panzuto;DELLE FAVE, Gianfranco
2009

Abstract

Gastroenteropancreatic endocrine tumours; (GEP ETs) represent a relatively rare and heterogeneous group of neoplasms whose therapy can be challenging. The poorly differentiated, fast-growing cases are treated with chemotherapy. In the slow-growing ones, biotherapy is usually performed. Several categories of targeted therapies have been studied for their treatment in vitro and in vivo. A critical review of molecular alterations suggests a rationale for targeting angiogenesis, and the phosphatidylinositol 3 kinase (PI(3)K)/AKT/mammalian target of rapamycin (mTOR) pathway. Accordingly, antiangiogenic agents and mTOR inhibitors are presently the most tested agents in phase II and III studies. Bevacizumab, some multitarget inhibitors, and mTOR inhibitors showed promising results in patients with advanced GEP ETs. A limited activity has been reported for imatinib and epidermal growth factor receptor (EGFR) inhibitors. Combinations of molecular targeted therapies with different sites of action, and somatostatin analogues may be relevant to avoid molecular escape pathways. Future trials should include more homogeneous groups of patients and pay more attention to the subgroup with progressive disease. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
2009
angiogenesis; carcinoids; mtor; pancreatic endocrine tumours; targeted therapy; tyrosine kinase
01 Pubblicazione su rivista::01a Articolo in rivista
Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives / Gabriele, Capurso; Nicola, Fazio; Stefano, Festa; Panzuto, Francesco; Filippo De Braud, ; DELLE FAVE, Gianfranco. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 72:2(2009), pp. 110-124. [10.1016/j.critrevonc.2009.01.008]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/364659
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 25
social impact